Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181313 | 0.85 | MAOA (0.41) | SLC6A4CYP2C19CYP2C9GRIN2DGRIN3B | |
| SCHEMBL14853093 | 0.85 | CYP2C19 (0.45) | SLC6A4CYP2C19CYP2C9GRIN2DGRIN3B | |
| SCHEMBL21622374 | 0.78 | ABHD6 (0.44) | HRH4CYP2C19CYP2C9 | |
| SCHEMBL19080449 | 0.78 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3CYP2C19CYP2D6 | |
| SCHEMBL19498190 | 0.77 | CYP1A2 (0.32) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL21626710 | 0.77 | LMNA (0.32) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL21622307 | 0.77 | JAK2 (0.34) | CYP2C19 | |
| SCHEMBL16664453 | 0.76 | HRH4 (0.32) | HRH4 | |
| SCHEMBL12341045 | 0.75 | HPGD (0.34) | CYP2C19 | |
| SCHEMBL12344128 | 0.75 | HRH3 (0.40) | SLC6A2SLC6A4SLC6A3HRH4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021098745-A1 | PREPARATION AND APPLICATION OF A CLASS OF PROTEIN RECEPTOR KINASE INHIBITORS | 上海轶诺药业有限公司 | 2021-05-27 | — | — | WO | disclosed |
| US-20210147436-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3822266-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020083377-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2020-04-30 | — | — | WO | disclosed |
| WO-2020011227-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | 南京明德新药研发有限公司 | 2020-01-16 | — | — | WO | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017005069-A1 | PYRROLIDINONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2017-01-12 | — | — | WO | disclosed |
| EP-2958910-B1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8865702-B2 | B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| WO-2014128486-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2014-08-28 | — | — | WO | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | CCR1 3468/4885CCR5 3416/4885CCR8 3849/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | CCR1 3789/4885CCR5 3484/4885CCR8 3944/4885 |
| US-20210147436-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | NGF, RET, NTRK1 | CCR1 3798/4885CCR5 2860/4885CCR8 3450/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | CCR1 3789/4885CCR5 3484/4885CCR8 3944/4885 |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | CCR1 3168/4885CCR5 3672/4885CCR8 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.